Leucine-Rich Repeat Kinase 2 inhibitor LRRK2-IN-1 (5mg)

ZZZZ_Status (Active, Disc) : Active

AA_Supplier Name : Biosensis

Alternative_Name (Other Names) :

Protein: Leucine-rich repeat serine/threonine-protein kinase 2; Dardarin; LRRK2; PARK8

Antibody_Isotype
(Antibody only) :

Application_Details :

Biosensis recommends optimal dilutions/concentrations should be determined by the end user.

Background_Info :

Clone_Name
(AB only, monoclonals) :

Datasheet_Link : http://www.biosensis.com/pdf_datasheet.php?products_id=1211

Description (Long Description) : 

Leucine-Rich Repeat Kinase 2 (LRRK2) is a member of the leucine-rich repeat kinase family. Mutations in the LRRK2 gene have been linked with late-onset autosomal dominant Parkinson€™s disease (PD). A recent screening identified the analog LRRK2-IN-1 as a potent and selective inhibitor of LRRK2. This research by Deng et al (2011, Nat Chem Biol) showed that LRRK2-IN-1 suppressed LRRK2 kinase activity in vivo leading to dephosphorylation of Ser910/Ser935, loss of 14-3-3 binding and accumulation of LRRK2 within aggregrate fibrillar structures. LRRK2-IN-1, is the first selective and potent inhibitor of LRRK2. LRRK2-IN-1 inhibits both wild-type and G2019S mutant LRRK2 kinase activity with IC50 values of 13nM and 6nM respectively (Deng et al 2011, Nat Chem Biol).

Expiry_Date : 

See storage conditions

Format (Form) : 

Dry, Synthetic chemical powder

Immunogen (Antigen) :

Kit_Components :

MSDS (File name) :